EMEA's consideration on strategy and design of clinical trials for new antibacterial agent;

FDA's general considerations on the antibacterial dugs clinical trial protocol issues and its enlightenment;

FDA's considerations of non-inferiority design used in anti-bacterial drug clinical trials;

Objective index for evaluating cerebral atherosclerosis in clinical trails;

Issues of clinical trails on traditional Chinese new drugs for diabetic polyneuropathy;

Some problems on clinical trails evalution of herbs medicine for insomnia;

Several Points in Ethic Review in Drug Clinical Trials;

Simulations of urn model and RPW rule of adaptive design in clinical trials;

Main points of design about phase I tolerant clinical trials of injectable preparation;